webinar register page

Webinar banner
IPVS Webinar - Your patient is HPV+: What is next?
Given the strong evidence that HPV-based screening is more effective than cytology or naked visual inspection after application of acetic acid, more and more countries have switched or are in the phase of switching towards screening using validated HPV assays. However, no consensus exists on how to triage HPV+ women. A comprehensive review of the literature on this topic provides clues to answer this question.

During this session, the experts will answer the following questions:
• When do we need a triage strategy after an HPV test?
• What are the best parameters for a triage strategy?
• Are the strategies for LMIC different from those of HIC?
* Required information


Marc Arbyn, PhD, MSc, MD
Coordinator Unit Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels. Professor at Department of Human
Marc Arbyn is coordinator of the Unit of Cancer Epidemiology at the Scientific Institute of Public Health in Brussels and guest professor at the University of Gent. He is also the representative of Belgium in the Scientific Council of the International Agency for Research on Cancer. The Unit of Cancer epidemiology is specialized in synthesizing evidence regarding application of new methods in the field of prevention and treatment of HPV-related (pre-)cancers. He is author of ~300 peer-reviewed papers, was editor in chief of the 2nd edition of European guidelines on cervical cancer screening and PI of several international fora dedicated to test evaluation.
Mark Schiffman, MD, MPH
National Cancer Institute, USA
Dr. Schiffman has studied human papillomavirus (HPV) and cervical cancer at NCI for almost 40 years. His natural history studies gave rise to translational research on HPV tests, serology, cytology, colposcopy, histology, and vaccines. With Dr. Nicolas Wentzensen, he is the Principal Investigator of the Cancer Cures “Moonshot” Initiative called “Accelerated Control of Cervical Cancer.” His priority is to validate screening methods and strategies, including self-sampled HPV typing tests and deep-learning approaches to classify cervical images, for resource-limited settings.
Karen Canfell, Professor and Director
The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW
Karen Canfell is an epidemiologist, modeller, and a translationally-focused population health researcher. She works across many countries to evaluate cervical cancer prevention and control and to support countries in implementation efforts. She also co-leads Compass, a major Australia RCT of cervical screening in an HPV-vaccinated population. Her team performed the first modelling of elimination in any country, and her work as one of the co-leads of the WHO Cervical Cancer Elimination Modelling Consortium on elimination supported the formal resolution by WHO to eliminate cervical cancer globally.